Topic Hub
5 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 5 of 5 clinical reviews.
A complete timeline of FDA label changes for Lantus (insulin glargine) from 2020 through 2026, including safety revisions, biosimilar interchangeability language, and post-market surveillance findings.
Read clinical reviewA detailed comparison of how the FDA and EMA approved, labeled, and monitor insulin glargine (Lantus), including biosimilar pathways, cancer signal investigations, and post-market surveillance differences.
Read clinical reviewA clinical review of FDA Adverse Event Reporting System (FAERS) data for Lantus (insulin glargine), covering hypoglycemia trends, cancer concerns resolved by ORIGIN, and ongoing pharmacovigilance signals.
Read clinical reviewA clinical review of Lantus (insulin glargine) patent litigation, FDA approval history, label evolution, and the legal battles that delayed biosimilar competition for over a decade.
Read clinical reviewA clinical review of the insulin glargine pipeline, next-generation basal insulins, biosimilars, and post-market regulatory updates for Lantus (glargine U-100).
Read clinical review